Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive‐stage small cell lung cancer: A meta‐analysis. (13th July 2017)

• Record Type: Journal Article
• Authors: Han, D.; Wang, G.; Sun, L.; Ren, X.; Shang, W.; Xu, L.; Li, S.
• Is Part Of: European journal of cancer care. Volume 26:Number 6(2017:Nov.)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-07-13
• Subjects: etoposide -- irinotecan -- meta‐analysis -- small cell lung carcinoma; Cancer -- Nursing -- Periodicals; 616.994
• DOI: 10.1111/ecc.12723
• Languages: English
• ISSNs: 0961-5423

Abstract

Abstract : This meta‐analysis was performed to compare the effects and toxicities between irinotecan/platinum (IP) and etoposide/platinum (EP) regimens as the fist‐line treatment of patients with extensive‐stage small cell lung cancer (E‐SCLC). A systematic search was made of MEDLINE, Cochrane, ISI Web of Science and SCOPUS databases. Randomised clinical trials on treatment of E‐SCLC with the IP regimens, compared with EP regimens, were reviewed. Studies were pooled to hazard ratio (HR), relative risk (RR) and odds ratio (OR), with 95% confidence interval (CI). Eight trials (enrolling 2089 participants) met the inclusion criteria. Overall survival (OS) and 1‐year survival rate were superior in the IP group (HR 0.83; 95% CI 0.75 to 0.91 and RR 1.19; 95% CI 1.06 to 1.34). Grades 3 and 4 anaemia, leukopenia, neutropenia, thrombocytopenia and febrile neutropenia were less frequent in the IP regimens than that in the EP regimens. And grades 3 and 4 nausea/vomiting, diarrheal, anorexia and fatigue were less frequent in the EP regimens. IP combination chemotherapy achieved a superior OS and 1‐year survival rate, compared with EP doublets, in patients with E‐SCLC.